Corcept raises 2026 revenue guidance to $950M-$1.05B as it targets $2B Cushing’s sales and $1B+ Lifyorli by decade-end

Q1 2026 earnings call recap: raised revenue guidance, Lifyorli FDA approval & launch metrics, relacorilant update, risks.

Big Pharma M&A set for mega year as patent expiries drive deal urgency

Biotech dealmaking is on pace for a bumper year in 2026, with large drugmakers on an acquisition spree to boost their ...

BioVaxys Presents Further Validation of the Robust Immune Response from a Combination of MVP-S with Checkpoint Inhibitors and Low-Dose Cyclophosphamide in Ovarian Cancer

TheNewswire - BioVaxys Technology Corp. (CSE: BIOV OTCQB:BVAXF FRA:5LB0), a clinical-stage immunotherapy company focused on transforming how the immune system targets and kills cancers, today ...

Moderna Reports First Quarter 2026 Financial Results and Provides Business Updates

Reports first quarter revenue of $0.4 billion, with approximately 80% of revenue from international marketsReports ...

Moderna expects up to 10% 2026 revenue growth and $4.5B-$5B year-end cash, while targeting ~$4.2B cash costs

Mock maintained cost targets and year-end liquidity outlook, stating, "we are expecting total GAAP operating expenses of $4.9 billion and cash costs of $4.2 billion" and "we expect to end 2026 with ...
Hosted on MSN

Biotech M&A surges to $84B as private credit faces scrutiny

Biotech mergers and acquisitions have reached $84 billion in early 2026, the fastest start since 2019, driven by looming patent expirations, strong cash reserves, and attractive valuations. Meanwhile, ...
Hosted on MSN

Biotech M&A surges as $300B patent cliff looms

Global biotech mergers and acquisitions are on track for one of their biggest years ever, with $84 billion in deals announced in the first quarter of 2026. Large pharmaceutical companies are racing to ...